戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 luded a CT scan, which now visualized a left adrenal tumor.
2 ometabolic outcomes compared with absence of adrenal tumors.
3 ypercortisolism or in 82 patients with other adrenal tumors.
4 to LTLA in the treatment of small and benign adrenal tumors.
5 en operating on pheochromocytomas and larger adrenal tumors.
6 method for treating small functional primary adrenal tumors.
7 he procedure for the most challenging of the adrenal tumors.
8 like growth factor II, have been reported in adrenal tumors.
9 ding the optimal evaluation and treatment of adrenal tumors.
10  higher risk for diabetes than those without adrenal tumors.
11 omen, seven men; mean age, 63 years) with 23 adrenal tumors (16 adenomas, six metastases, one adrenoc
12 cident composite diabetes than those without adrenal tumors (30 of 110 [27.3%] vs. 72 of 615 [11.7%]
13                                        Of 64 adrenal tumors, 55 were initially considered benign, 6 h
14 y of cross-sectional imaging in detection of adrenal tumors, adrenal venous sampling may be selective
15            Perhaps most significantly, MEN2A adrenal tumors also display these changes in cell cycle
16 r in childhood/adolescence had primary extra-adrenal tumors and harbored SDHB mutations.
17 terization studies, are useful in localizing adrenal tumors and in distinguishing between benign and
18  the preferred technique for removing benign adrenal tumors and isolated metastases.
19 mice bearing either s.c. or orthotopic intra-adrenal tumors, and 40% of mice bearing induced metastat
20                           Background: Benign adrenal tumors are commonly discovered on abdominal imag
21                                       Benign adrenal tumors are commonly discovered on cross-sectiona
22                                 Most primary adrenal tumors are sporadic, but may be associated with
23                                              Adrenal tumors are very common, with the majority being
24 ment of whether the classification of benign adrenal tumors as "nonfunctional" adequately reflects th
25                                              Adrenal tumors autonomously producing cortisol cause Cus
26  choice for functional and primary malignant adrenal tumors, both for cure and palliation, with low m
27 NH(-/-)-LH-CTP mice not only fail to develop adrenal tumors but have smaller adrenals, with a regress
28 but exhibited residual toxicity on mouse Y-1 adrenal tumor cells and had an ability equivalent to tha
29  aberrant expression of ectopic receptors on adrenal tumor cells have been implicated in adrenal cell
30  galactose and to GM1, toxicity on mouse Y-1 adrenal tumor cells, the ability to stimulate adenylate
31                                              Adrenal tumors driving hormone excess, like primary aldo
32                                              Adrenal tumors evoke considerable interest and diagnosti
33 r 31, 2019, and control participants without adrenal tumors followed up until death or the end of 201
34 vated LH levels are not sufficient to induce adrenal tumor formation.
35                                Evaluation of adrenal tumors from 118 adult patients demonstrated an i
36 nd treatment approaches in the management of adrenal tumors; further research is necessary.
37 upports the conclusion that activin inhibits adrenal tumor growth by inducing x-zone regression.
38                                          New adrenal tumors have also been associated with nonheredit
39 ional imaging is recommended to characterize adrenal tumors; however, mistakes may occur and therefor
40 mon presentation was that of a single benign adrenal tumor in patients older than 40 years.
41                    All mutation carriers had adrenal tumors, including 7 bilateral (P = 2.7 x 10(-4))
42 concentration; this patient had a very small adrenal tumor (<1 cm).
43  (serum cortisol: <50 nmol/L, nonfunctioning adrenal tumor [NFAT]; 50 to 138 nmol/L, possible MACS [M
44          It is unclear whether nonfunctional adrenal tumors (NFATs) are associated with fractures.
45 o evaluate the hypothesis that nonfunctional adrenal tumors (NFATs) increase risk for cardiometabolic
46 identalomas are mostly benign nonfunctioning adrenal tumors (NFATs) or adenomas causing mild autonomo
47                                        Extra-adrenal tumors occurred in 28 mutation carriers (48%) an
48 nes, and all had radiographic evidence of an adrenal tumor or tumors.
49                                          The adrenal tumor pheochromocytoma (PCC) can be caused by ac
50 functional variants previously implicated in adrenal tumor predisposition, and one (Y727C) was a know
51 ctors negatively associated with OS included adrenal tumor size (P < 0.01), renal primary versus othe
52 tastases did not differ with respect to age, adrenal tumor size, or margin status.
53 sterase 11A (PDE11A) have been implicated in adrenal tumor susceptibility.
54 TP mice develop large, sex steroid-producing adrenal tumors that arise from the x zone, indicating a
55 MRI fail to characterize the pathogenesis of adrenal tumors, the use of specialized molecular imaging
56 sistent with Li-Fraumeni syndrome-associated adrenal tumors, there was no history of increased cancer
57 n several familial syndromes associated with adrenal tumors; these include menin, which is responsibl
58 enalectomy the method of choice for removing adrenal tumors; this type of surgery allows shorter hosp
59 NFATs ("exposed"; n = 166) and those with no adrenal tumor ("unexposed"; n = 740), with at least 3 ye
60 ients (undergoing 13 procedures) with single adrenal tumors were included in the analysis.
61 ncreases with age, appropriate management of adrenal tumors will be a growing challenge in our aging
62 t reliable parameter for characterization of adrenal tumors with 3.0-T MR imaging when obtaining OP e